

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ALDURAZYME safely and effectively. See full prescribing information for ALDURAZYME.

ALDURAZYME (laronidase)
Solution for intravenous infusion only
Initial U.S. Approval: 2003

WARNING: RISK OF ANAPHYLAXIS.

See full prescribing information for complete boxed warning.
Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is administered. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

RECENT MAJOR CHANGES

Boxed Warning (4/2008); Warnings and Precautions (5) (4/2008)

INDICATIONS AND USAGE

ALDURAZYME is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risk and benefits of treating mildly affected patients with Scheie form have not been established. ALDURAZYME has been shown to improve pulmonary function and walking capacity. ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder (1).

DOSAGE AND ADMINISTRATION

- 0.58 mg/kg of body weight administered once weekly as an intravenous (IV) infusion (2).

DOSAGE FORMS AND STRENGTHS

Solution for IV infusion: 2.9 mg/5 ml vial (3).

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

- Life-threatening anaphylactic reactions have been observed in some patients during or up to 3 hours after infusion. Patients with an acute illness at the time of infusion may be at greater risk for infusion-related reactions. Appropriate medical support should be available when ALDURAZYME is administered. If anaphylactic or other severe allergic reactions occur, immediately discontinue the infusion and initiate appropriate treatment, which may include ventilatory support, treatment with inhaled beta-adrenergic agonists, epinephrine, and IV corticosteroids (5.1).
- Pretreatment with antipyretics and/or antihistamines is recommended prior to the infusion to reduce the risk of infusion-related allergic reactions. If infusion-related reactions occur, decreasing the infusion rate, temporarily stopping the infusion, and/or administering additional antipyretics and/or antihistamines may ameliorate the symptoms (5.1).

ADVERSE REACTIONS

The most frequently occurring adverse reactions occurring in at least 10% of patients 6 years and older are rash, upper respiratory tract infection, injection site reaction, hyperreflexia, paresthesia, and vein disorder. The most commonly reported adverse reactions occurring in at least 10% of patients less than 6 years of age were pyrexia, chills, increased blood pressure, tachycardia, and decreased oxygen saturation (6).

To report SUSPECTED ADVERSE REACTIONS, contact: Genzyme at 1-800-745-4447, or FDA at 1-800-FDA-1088 or go to www.fda.gov/medwatch

USE IN SPECIFIC POPULATIONS

A registry for pregnant women is available. Pregnant women with MPS I who are treated with ALDURAZYME should be encouraged to enroll in the MPS I Registry. For more information, visit www.MPSRegistry.com or call (800) 745-4447 (8.1).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: X/200X

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: RISK OF ANAPHYLAXIS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

2.2 Instructions for Use

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Anaphylaxis and Allergic Reactions

6 ADVERSE REACTIONS

6.1 Adverse Reactions in Clinical Studies

6.2 Immunogenicity

6.3 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Labor and Delivery

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the Full Prescribing Information are not listed

1 **FULL PRESCRIBING INFORMATION**

2
3 **WARNING: RISK OF ANAPHYLAXIS.**

4 **Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME[®]**
5 **infusions. Therefore, appropriate medical support should be readily available when ALDURAZYME is**
6 **administered. Patients with compromised respiratory function or acute respiratory disease may be at risk**
7 **of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require**
8 **additional monitoring.**
9

10
11 **1 INDICATIONS AND USAGE**
12

13 ALDURAZYME is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I)
14 and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating
15 mildly affected patients with the Scheie form have not been established.

16 ALDURAZYME has been shown to improve pulmonary function and walking capacity. ALDURAZYME has not
17 been evaluated for effects on the central nervous system manifestations of the disorder.
18

19 **2. DOSAGE AND ADMINISTRATION**

20 **2.1 Recommended Dose**

21 The recommended dosage regimen of ALDURAZYME is 0.58 mg/kg of body weight administered once weekly as
22 an intravenous (IV) infusion. Pretreatment with antipyretics and/or antihistamines is recommended 60 minutes prior
23 to the start of the infusion [*see Warnings and Precautions (5)*].

24 **2.2 Instructions for Use**

25 Prepare and use ALDURAZYME according to the following steps.

- 26 1. Each vial of ALDURAZYME provides 2.9 milligrams (mg) of laronidase in 5.0 milliliters (mL) of solution
27 and is intended for single use only. Do not use the vial more than one time. The concentrated solution for
28 infusion must be diluted with 0.1% Albumin (Human) in 0.9% Sodium Chloride Injection, USP using
29 aseptic techniques. Prepare ALDURAZYME using PVC containers and administer with a PVC infusion
30 set equipped with an in-line, low protein binding 0.2 micrometer (μ m) filter. There is no information on
31 the compatibility of diluted ALDURAZYME with glass containers.
- 32 2. The total volume of the infusion is determined by the patient's body weight. Patients with a body weight of
33 20 kg or less should receive a total volume of 100 mL. Patients with a body weight of greater than 20 kg
34 should receive a total volume of 250 mL. Determine the number of vials to be diluted based on the
35 individual patient's weight and the recommended dose of 0.58 mg/kg, using the following equation:
36
$$[\text{Patient's weight (kg)} \times 1 \text{ mL/kg of ALDURAZYME} = \text{Total \# mL of ALDURAZYME, then}$$

37
$$\text{Total \# of mL of ALDURAZYME} \div 5 \text{ mL per Vial} = \text{Total \# of Vials}].$$
- 38 3. Round up to the nearest whole vial. Remove the required number of vials from the refrigerator to allow
39 them to reach room temperature. Do not heat or microwave vials.
- 40 4. Before withdrawing the ALDURAZYME from the vial, visually inspect each vial for particulate matter and
41 discoloration. The ALDURAZYME solution should be clear to slightly opalescent and colorless to pale
42 yellow. A few translucent particles may be present. Do not use if the solution is discolored or if there is
43 particulate matter in the solution.
- 44 5. Using *Table 1* as a guide, prepare an infusion bag of 0.1% Albumin (Human) in 0.9% Sodium Chloride
45 Injection, USP. Remove and discard a volume of 0.9% Sodium Chloride Injection, USP equal to the
46 volume of Albumin (Human) to be added to the infusion bag. Add the appropriate volume of Albumin
47 (Human) to the infusion bag and gently rotate the infusion bag to ensure proper distribution of the
48 Albumin.

49

Table 1: Amount of Albumin (Human) Required in Infusion Solution

Total Volume of ALDURAZYME Infusion	Volume of Albumin (Human) [5% solution] to be Added	Volume of Albumin (Human) [25% solution] to be Added
100 mL	2 mL	0.4 mL
250 mL	5 mL	1 mL

- 50 6. Withdraw and discard a volume of the 0.1% Albumin (Human) in 0.9% Sodium Chloride Injection, USP
51 from the infusion bag, equal to the volume of ALDURAZYME concentrate to be added.
- 52 7. Slowly withdraw the calculated volume of ALDURAZYME from the appropriate number of vials using
53 caution to avoid excessive agitation. Do not use a filter needle, as this may cause agitation. Agitation may
54 denature ALDURAZYME, rendering it biologically inactive.
- 55 8. Slowly add the ALDURAZYME solution to the 0.1% Albumin (Human) in 0.9% Sodium Chloride
56 Injection, USP using care to avoid agitation of the solutions. Do not use a filter needle.
- 57 9. Gently rotate the infusion bag to ensure proper distribution of ALDURAZYME. Do not shake the solution.
- 58 10. The entire infusion volume (100 mL for patients weighing 20 kg or less and 250 mL for patients weighing
59 20 kg or greater) should be delivered over approximately 3 to 4 hours. The initial infusion rate of 10
60 µg/kg/hr may be incrementally increased every 15 minutes during the first hour, as tolerated, until a
61 maximum infusion rate of 200 µg/kg/hr is reached. The maximum rate is then maintained for the
62 remainder of the infusion (2-3 hours), as outlined in *Tables 2 and 3*.

**Table 2: Incremental Rates for 100 mL ALDURAZYME Infusion
(For use with Patients Weighing 20 kg or Less)**

63
64

Infusion Rate	Criteria for Increasing Infusion Rate
2 mL/hr x 15 minutes (10 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
4 mL/hr x 15 minutes (20 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
8 mL/hr x 15 minutes (50 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
16 mL/hr x 15 minutes (100 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
32 mL/hr x ~3 hours (200 µg/kg/hr)	For the remainder of the infusion.

65
66
67
68
69
70
71
72
73
74
75

76
77

**Table 3: Incremental Rates for 250 mL ALDURAZYME Infusion
(For use with Patients Weighing 20 kg or Greater)**

Infusion Rate	Criteria for Increasing Infusion Rate
5 mL/hr x 15 minutes (10 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
10 mL/hr x 15 minutes (20 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
20 mL/hr x 15 minutes (50 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
40 mL/hr x 15 minutes (100 µg/kg/hr)	Obtain vital signs, if stable then increase the rate to...
80 mL/hr x ~3 hours (200 µg/kg/hr)	For the remainder of the infusion.

78

79 ALDURAZYME must not be mixed with other medicinal products in the same infusion. The compatibility of
80 ALDURAZYME in solution with other products has not been evaluated.

81

82 **3. DOSAGE FORMS AND STRENGTHS**

83 ALDURAZYME is supplied as a sterile solution in clear Type I glass 5 mL vials (2.9 mg laronidase per 5 mL).

84

85 **4 CONTRAINDICATIONS**

86 None.

87 **5 WARNINGS AND PRECAUTIONS**

88 **5.1 Anaphylaxis and Allergic Reactions** [see *Boxed Warning*]

89 Life-threatening anaphylactic reactions have been observed in some patients during or up to 3 hours after
90 ALDURAZYME infusions. Reactions have included respiratory failure, respiratory distress, stridor, tachypnea,
91 bronchospasm, airway obstruction, hypoxia, hypotension, bradycardia, and urticaria. Interventions have included
92 resuscitation, mechanical ventilatory support, emergency tracheotomy, hospitalization, and treatment with inhaled
93 beta-adrenergic agonists, epinephrine, and IV corticosteroids.

94 In clinical studies and postmarketing safety experience with ALDURAZYME, approximately 1% of patients
95 experienced severe or serious allergic reactions. In patients with MPS I, pre-existing upper airway obstruction may
96 have contributed to the severity of some reactions. Due to the potential for severe allergic reactions, appropriate
97 medical support should be readily available when ALDURAZYME is administered. Because of the potential for
98 recurrent reactions, some patients who experience initial severe reactions may require prolonged observation.

99

100 Patients with an acute illness at the time of ALDURAZYME infusion may be at greater risk for infusion-related
101 reactions. Careful consideration should be given to the patient's clinical status prior to administration of
102 ALDURAZYME. One patient with acute bronchitis and hypoxia experienced increased tachypnea during the first
103 ALDURAZYME infusion that resolved without intervention. The patient's respiratory symptoms returned within
104 30 minutes of completing the infusion and responded to bronchodilator therapy. Approximately 6 hours after the
105 infusion, the patient experienced coughing, then respiratory arrest, and died.

106

107 Patients should receive antipyretics and/or antihistamines prior to infusion [see *Adverse Reactions (6); Dosage and*
108 *Administration (2.1)*]. If an infusion-related reaction occurs, regardless of pre-treatment, decreasing the infusion
109 rate, temporarily stopping the infusion, and/or administering additional antipyretics and/or antihistamines may
110 ameliorate the symptoms [see *Adverse Reactions (6)*].

111 If anaphylactic or other severe allergic reactions occur, immediately discontinue the infusion of ALDURAZYME
112 and initiate appropriate treatment. Caution should be exercised if epinephrine is being considered for use in patients
113 with MPS I due to the increased prevalence of coronary artery disease in these patients.

114 The risks and benefits of re-administering ALDURAZYME following an anaphylactic or severe allergic reaction
115 should be considered. Extreme care should be exercised, with appropriate resuscitation measures available, if the
116 decision is made to re-administer the product.

117 **6 ADVERSE REACTIONS**

118 **6.1 Adverse Reactions in Clinical Studies**

119 The most serious adverse reactions reported with ALDURAZYME treatment during clinical studies were
120 anaphylactic and allergic reactions [*see Boxed Warning and Warnings and Precautions (5)*]. Most adverse events
121 reported in clinical studies were considered disease-related and unrelated to study drug. The most common adverse
122 reactions were infusion-related reactions. The frequency of infusion-related reactions decreased over time with
123 continued use of Aldurazyme, and the majority of reactions were classified as being mild to moderate in severity.
124 Most infusion-related reactions requiring intervention were ameliorated with slowing of the infusion rate,
125 temporarily stopping the infusion, and/or administering additional antipyretics and/or antihistamines [*see Warnings
126 and Precautions (5)*].
127

128 **6.1.1 Clinical Studies in Patients 6 Years and Older**

129 In a 26-week, double-blind, placebo-controlled clinical study (Study 1) of ALDURAZYME in 45 patients with
130 MPS I, ages 6 to 43 years old, in which all patients were treated with antipyretics and antihistamines prior to the
131 infusions, infusion-related reactions were reported in 32% (7 of 22) of ALDURAZYME treated patients. The most
132 commonly reported infusion-related reactions were flushing, fever, headache and rash. Flushing occurred in 5
133 patients (23%) receiving ALDURAZYME; the other reactions were less frequent. Less common infusion-related
134 reactions included cough, bronchospasm, dyspnea, urticaria, angioedema, and pruritus.
135

136 The data (*Table 4*) described below reflect exposure to 0.58 mg/kg of ALDURAZYME for 26 weeks in Study 1.
137 The population in Study 1 was evenly distributed for gender (N=23 females and 22 males). Of these 45 patients,
138 1 was clinically assessed as having Hurler form, 37 Hurler-Scheie, and 7 Scheie.

139 Because clinical studies are conducted under widely varying conditions, the adverse reaction rates cannot be directly
140 compared to rates in the clinical trial of another drug and may not reflect the rates observed in patients in clinical
141 practice.

142 *Table 4* enumerates adverse reactions and selected laboratory abnormalities that occurred during the placebo-
143 controlled study (Study 1) that were reported in at least 2 patients more in the ALDURAZYME group than in the
144 placebo group.

145 **Table 4: Summary of Adverse Reactions that Occurred in 2 Patients More in the ALDURAZYME Group**
146 **than in the Placebo Group in the 26-Week Placebo-controlled Study (Study 1)***
147

Adverse Event	ALDURAZYME (N=22) n (%)	Placebo (N=23) n (%)
Respiratory System		
Upper respiratory tract infection	7 (32)	4 (17)
Body as a Whole		
Chest pain	2 (9)	0
Nervous System		
Hyperreflexia	3 (14)	0
Paresthesia	3 (14)	1 (4)
Skin and Appendages		
Rash	8 (36)	5 (22)
Resistance Mechanism		
Abscess	2 (9)	0
Liver and Biliary System		
Bilirubinemia	2 (9)	0
Vascular		
Vein disorder	3 (14)	1 (4)
Urinary System		
Facial edema	2 (9)	0
Cardiovascular, General		
Hypotension	2 (9)	0
Dependent edema	2 (9)	0
Vision		
Corneal opacity	2 (9)	0
Application Site		
Injection site pain	2 (9)	0
Injection site reaction	4 (18)	2 (9)
Platelet, Bleeding and Clotting		
Thrombocytopenia	2 (9)	0

148 *Reported adverse reactions were classified using WHOART terminology.
149

150 All 45 patients who completed the placebo-controlled study (Study 1) continued treatment in an open-label,
151 uncontrolled extension study (Study 2). All patients received ALDURAZYME 0.58 mg/kg of body weight once
152 weekly for up to 182 weeks. The most serious adverse reactions reported with ALDURAZYME infusions in Study
153 2 were anaphylactic and allergic reactions [*see Warnings and Precautions (5)*]. The most common adverse reactions
154 requiring intervention were infusion-related reactions reported in 49% (22 of 45) of patients treated with
155 ALDURAZYME. The most commonly reported infusion-related reactions included rash (13%), flushing (11%),
156 fever (11%), headache (9%), abdominal pain (9%), and injection site reaction (9%). Less commonly reported
157 infusion-related reactions included diarrhea (7%), nausea (7%), temperature changed sensation (7%), vomiting
158 (4%), and hypotension (4%). The most common adverse events (regardless of relationship) included rhinitis,
159 headache, fever, cough, pharyngitis, nausea, pain, arthralgia, diarrhea, vomiting, skeletal pain, upper respiratory
160 infection, abdominal pain, back pain, and rash.

161

162 **6.1.2 Clinical Studies in Patients 6 Years and Younger**

163 Study 3 was a 52-week open-label, uncontrolled study of 20 MPS I patients, ages 6 months to 5 years old (at
164 enrollment). Sixteen patients were clinically assessed as having the Hurler form, and 4 had the Hurler-Scheie form.
165 All 20 patients received ALDURAZYME at 0.58 mg/kg of body weight once weekly for 26 weeks and up to 52
166 weeks. All patients were treated with antipyretics and antihistamines prior to the infusions.

167 The most commonly reported serious adverse events (regardless of relationship) reported with ALDURAZYME
168 infusions in Study 3 were otitis media (20%), and venous catheterization required for ALDURAYZME infusion
169 (15%).

170 The nature and severity of infusion-related reactions were similar between the older and less severely affected
171 patients in Studies 1 and 2, and the younger, more severely affected patients in Study 3. The most commonly
172 reported adverse reactions in Study 3 were infusion-related reactions reported in 35% (7 of 20) of patients and
173 included pyrexia (30%), chills (20%), blood pressure increased (10%), tachycardia (10%), and oxygen saturation
174 decreased (10%). Other infusion-related reactions occurring in $\geq 5\%$ of patients were pallor, tremor, respiratory
175 distress, wheezing, crepitations (pulmonary), pruritis, and rash.

176 Other commonly reported adverse events were cough, diarrhea, vomiting, rhinorrhea, rhinitis, and otorrhea.

177 **6.2 Immunogenicity**

178 In clinical studies, 99 of 102 patients (97%) treated with ALDURAZYME were positive for IgG antibodies to
179 ALDURAZYME. The clinical significance of antibodies to ALDURAZYME, including the potential for product
180 neutralization, is not known. Potential for antibody neutralization of cellular uptake has not been assessed.

181 The data reflect the percentage of patients whose test results were considered positive for antibodies to
182 ALDURAZYME using an enzyme-linked immunosorbent assay (ELISA) for ALDURAZYME-specific IgG binding
183 antibodies reported as titers (57 patients) or optical density units per uL (OD/uL) (42 patients), and confirmed by
184 radio-immunoprecipitation (RIP). The relationship of ALDURAZYME antibody concentration in titer units and
185 OD/uL units has not been established.

186 Nine patients in Study 1 and Study 2, collectively, who experienced severe infusion-related reactions were tested for
187 ALDURAZYME-specific IgE antibodies and complement activation. IgE testing was performed by ELISA, and
188 complement activation was measured by the Quidel Enzyme Immunoassay. One of the nine patients had an
189 anaphylactic reaction consisting of urticaria and airway obstruction and tested positive for both ALDURAZYME-
190 specific IgE binding antibodies and complement activation [*see Warnings and Precautions (5)*]. None of the
191 patients in the open-label clinical study of patients 5 years old or younger (Study 3) tested positive for IgE.

192 Other allergic reactions were also seen in patients receiving ALDURAZYME [*see Adverse Reactions (6)*].

193 In the postmarketing setting, approximately 1% of patients experienced severe or serious infusion-related allergic
194 reactions and tested positive for IgE [*see Warnings and Precautions (5)*]. Of these IgE-positive patients, some have
195 discontinued treatment, but some have been successfully re-challenged. The clinical significance of IgE antibodies
196 has not been established.

197 As with all the therapeutic proteins, there is potential for immunogenicity. The incidence of antibody formation is
198 highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody
199 (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay
200 methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For
201 these reasons, comparison of the incidence of antibodies to ALDURAZYME with the incidence of antibodies to
202 other products may be misleading.

204 **6.3 Postmarketing Experience**

205 In postmarketing experience with ALDURAZYME, severe and serious infusion-related reactions have been
206 reported, some of which were life-threatening [*see Boxed Warning and Warnings and Precautions (5)*].

207 The most common adverse reactions (using MedDRA terminology) included chills, vomiting, nausea, arthralgia,
208 diarrhea, tachycardia, abdominal pain, blood pressure increased, and oxygen saturation decreased. Because these
209 reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate
210 their frequency or establish a causal relationship to drug exposure.

211 **7 DRUG INTERACTIONS**

212 No formal drug interaction studies were performed.

213 **8 USE IN SPECIFIC POPULATIONS**

214 **8.1 Pregnancy**

215 Pregnancy Category B.

216 A developmental toxicity study has been performed in rats at doses up to 6.2 times the human dose and has revealed
217 no evidence of impaired fertility or harm to the fetus due to ALDURAZYME. However, there are no adequate and
218 well-controlled studies of ALDURAZYME in pregnant women. Because animal reproduction studies are not
219 always predictive of human response, this drug should be used during pregnancy only if clearly needed.

220 Pregnant women with MPS I who are treated with ALDURAZYME should be encouraged to enroll in the MPS I
221 Registry. For more information, visit www.MPSRegistry.com or call (800) 745-4447 [*see Patient Counseling*
222 *Information (17)*].

223 **8.2 Labor and Delivery**

224 There is no information on the effect of ALDURAZYME during labor and delivery. Pregnant women with MPS I
225 who are treated with ALDURAZYME should be encouraged to enroll in the MPS I Registry [*see Patient Counseling*
226 *Information (17)*].

227 **8.3 Nursing Mothers**

228 It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk,
229 caution should be exercised when ALDURAZYME is administered to a nursing woman.

230 Nursing mothers with MPS I who are treated with ALDURAZYME should be encouraged to enroll in the MPS I
231 Registry [*see Patient Counseling Information (17)*].

232 **8.4 Pediatric Use**

233 The safety and effectiveness of ALDURAZYME was assessed in a 52-week, open-label, uncontrolled clinical study
234 in 20 patients with MPS I, ages 6 months to 5 years old, and was found to be similar to the safety and effectiveness
235 of ALDURAZYME in pediatric patients 6 to 18 years, and adults [*see Adverse Reactions (6) and Clinical Studies*
236 *(14)*].

237 **8.5 Geriatric Use**

238 Clinical studies of ALDURAZYME did not include patients aged 65 and over. It is not known whether they
239 respond differently from younger patients.

240 **10 OVERDOSAGE**

241 There have been no reports of overdose with ALDURAZYME. In clinical studies, a small number of patients
242 received doses up to 1.2 mg/kg body weight once weekly or 1.8 mg/kg body weight every other week. Adverse
243 events reported in patients receiving 1.2 mg/kg body weight once weekly or 1.8 mg/kg body weight every other
244 week were similar to the adverse reactions reported by patients treated with 0.58 mg/kg body weight once weekly.
245

246 **11 DESCRIPTION**

247 ALDURAZYME (laronidase) is a polymorphic variant of the human enzyme α -L-iduronidase that is produced by
248 recombinant DNA technology in a Chinese hamster ovary cell line. α -L-iduronidase (glycosaminoglycan α -L-
249 iduronohydrolase, EC 3.2.1.76) is a lysosomal hydrolase that catalyses the hydrolysis of terminal α -L-iduronic acid
250 residues of dermatan sulfate and heparan sulfate.

251 Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence
252 of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of
253 human α -L-iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus
254 and contains 6 N-linked oligosaccharide modification sites. Two oligosaccharide chains terminate in mannose-6-
255 phosphate sugars. ALDURAZYME has a specific activity of approximately 172 U/mg.

256 ALDURAZYME, for IV infusion, is supplied as a sterile, nonpyrogenic, colorless to pale yellow, clear to slightly
257 opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP, containing

258 0.1% Albumin (Human). The solution in each vial contains a nominal laronidase concentration of 0.58 mg/mL and
259 a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg laronidase, 43.9 mg
260 sodium chloride, 63.5 mg sodium phosphate monobasic monohydrate, 10.7 mg sodium phosphate dibasic
261 heptahydrate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use
262 only.

263 12 CLINICAL PHARMACOLOGY

264 12.1 Mechanism of Action

265 Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the
266 catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis I (MPS I) is characterized by the deficiency of
267 α -L-iduronidase, a lysosomal hydrolase which catalyses the hydrolysis of terminal α -L-iduronic acid residues of
268 dermatan sulfate and heparan sulfate. Reduced or absent α -L-iduronidase activity results in the accumulation of the
269 GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue,
270 and organ dysfunction.

271 The rationale of ALDURAZYME therapy in MPS I is to provide exogenous enzyme for uptake into lysosomes and
272 increase the catabolism of GAG. ALDURAZYME uptake by cells into lysosomes is most likely mediated by the
273 mannose-6-phosphate-terminated oligosaccharide chains of laronidase binding to specific mannose-6-phosphate
274 receptors.

275 Because many proteins in the blood are restricted from entry into the central nervous system (CNS) by the blood
276 brain barrier, effects of intravenously administered ALDURAZYME on cells within the CNS cannot be inferred
277 from activity in sites outside the CNS. The ability of ALDURAZYME to cross the blood brain barrier has not been
278 evaluated in animal models or in clinical studies.

279 12.2 Pharmacodynamics

280 The pharmacodynamic effect of ALDURAZYME was assessed by reductions in urinary GAG levels. The
281 responsiveness of urinary GAG to dosage alterations of ALDURAZYME is unknown, and the relationship of
282 urinary GAG to other measures of clinical response has also not been established [*see Clinical Studies (14)*].

283 12.3 Pharmacokinetics

284 The pharmacokinetics of laronidase were evaluated in 6 year old or older patients (N = 10 to 12) with MPS I who
285 received 0.58 mg/kg of body weight once weekly of ALDURAZYME as a 4-hour infusion in the placebo-controlled
286 clinical study (Study 1). After the 1st, 12th, and 26th weekly infusions, the mean maximum plasma concentrations
287 (C_{max}) ranged from 1.2 to 1.7 μ g/mL for the 3 time points. The mean area under the plasma concentration-time
288 curve (AUC_{∞}) ranged from 4.5 to 6.9 μ g • hour/mL. The mean volume of distribution (V_z) ranged from 0.24 to 0.6
289 L/kg. Mean plasma clearance (CL) ranged from 1.7 to 2.7 mL/min/kg, and the mean elimination half-life ($t_{1/2}$)
290 ranged from 1.5 to 3.6 hours.

291 Most patients who received once weekly infusions of ALDURAZYME in Study 1 developed antibodies to
292 laronidase by Week 12. Between Weeks 1 and 12, increases in the plasma clearance of laronidase were observed in
293 some patients and appeared to be proportional to the antibody titer. At Week 26, plasma clearance of laronidase was
294 comparable to that at Week 1, in spite of the continued and, in some cases, increased titers of antibodies.

295 The pharmacokinetics of ALDURAZYME have not been established in patients 6 years and younger.

296 13 NONCLINICAL TOXICOLOGY

297 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

298 Studies to assess the mutagenic and carcinogenic potential of laronidase have not been conducted.

299 Laronidase at IV doses up to 3.6 mg/kg (6.2 times the human dose) was found to have no effect on the fertility and
300 reproductive performance of male and female rats.

301 14 CLINICAL STUDIES

302 The safety and efficacy of ALDURAZYME were assessed in three clinical studies.

303 **14.1 Clinical Studies in Patients 6 Years and Older**

304 Study 1 was a randomized, double-blind, placebo-controlled study in 45 patients with MPS I, ages 6 to 43 years old,
305 including 1 patient with the Hurler form, 37 patients with Hurler-Scheie form, and 7 patients with Scheie form of
306 MPS I. All patients had a baseline percent predicted forced vital capacity (FVC) less than or equal to 77%. Patients
307 received ALDURAZYME at 0.58 mg/kg of body weight once weekly or placebo once weekly for 26 weeks. All
308 patients were treated with antipyretics and antihistamines prior to each infusion.

309 The primary efficacy outcome assessments were percent predicted FVC and distance walked in 6 minutes (6-minute
310 walk test). After 26 weeks, patients treated with ALDURAZYME showed improvement in percent predicted FVC
311 and in 6-minute walk test compared to placebo-treated patients (*see Table 5*).

312

313

Table 5: Primary Efficacy Outcomes in the Placebo-controlled Study (Study 1)

		ALDURAZYME (N = 22)	Placebo (N = 23)
Forced Vital Capacity (percent of predicted normal)			
Pre-treatment Baseline	Mean ± s.d.	48 ± 15	54 ± 16
Week 26	Mean ± s.d.	50 ± 17	51 ± 13
Change from Baseline to Week 26	Mean ± s.d.	1 ± 7	-3 ± 7
	Median	1	-1
Difference in Change from Baseline to Week 26 Between Groups	Mean	4	
	Median (95% CI)	2 (0.4, 7), p=0.02*	
6-Minute Walk Distance (meters)			
Pre-treatment Baseline	Mean ± s.d.	319 ± 131	367 ± 114
Week 26	Mean ± s.d.	339 ± 127	348 ± 129
Change from Baseline to Week 26	Mean ± s.d.	20 ± 69	-18 ± 67
	Median	28	-11
Difference in Change from Baseline to Week 26 Between Groups	Mean	38	
	Median (95% CI)	39 (-2, 79), p=0.07*	

314

* By Wilcoxon Rank Sum Test

315 Evaluations of bioactivity were changes in liver size and urinary GAG levels. Liver size and urinary GAG levels
316 decreased in patients treated with ALDURAZYME compared to patients treated with placebo. No patient in the
317 group receiving ALDURAZYME reached the normal range for urinary GAG levels during this 6-month study.

318 Study 2 was a 182-week, open-label, uncontrolled extension study of all 45 patients who completed Study 1.
319 Patients received ALDURAZYME at 0.58 mg/kg body weight once weekly. For patients treated with
320 ALDURAZYME, the mean increase in 6-minute walk test distance was maintained for an additional 182 weeks
321 through completion of Study 2.

322 At the end of Study 2, the decrease in mean urinary GAG was similar to the decrease in urinary GAG reported in
323 ALDURAZYME treated patients at the end of Study 1. The relationship of urinary GAG to other measures of
324 clinical response has not been established [*see Clinical Pharmacology (12.2)*].

325 **14.2 Clinical Studies in Patients 6 Years and Younger**

326 Study 3 was a 52-week, open-label, uncontrolled clinical study in 20 patients with MPS I, ages 6 months to 5 years
327 old (at enrollment), including 16 patients (80%) with the Hurler form and 4 patients (20%) with the Hurler-Scheie
328 form. All 20 patients received ALDURAZYME at 0.58 mg/kg of body weight once weekly for 26 weeks. After 26
329 weeks of treatment, 16 patients continued to receive 0.58 mg/kg of body weight once weekly through Week 52, and
330 4 patients received 1.16 mg/kg of body weight once weekly from Week 26 through Week 52.

331 Reduction in mean urinary GAG was demonstrated at Week 13 and was maintained through Week 52. No patient
332 receiving ALDURAZYME reached the normal range for urinary GAG levels during this 52-week study. Changes in
333 urinary GAG levels in children 6 years and younger were similar to changes reported in older patients in Studies 1
334 and 2 (6 through 43 years old). The relationship of urinary GAG to other measures of clinical response has not been
335 established [*see Clinical Pharmacology (12.2)*].

336 **16 HOW SUPPLIED/STORAGE AND HANDLING**

337 ALDURAZYME is supplied as a sterile solution in clear Type I glass 5 mL vials (2.9 mg laronidase per 5 mL). The
338 closure consists of a siliconized butyl stopper and an aluminum seal with a plastic flip-off cap.

339 NDC 58468-0070-1, 5 mL vial

340 Refrigerate vials of ALDURAZYME at 2° to 8°C (36° to 46°F). DO NOT FREEZE OR SHAKE. DO NOT USE
341 ALDURAZYME after the expiration date on the vial. This product contains no preservatives.

342 The diluted solution should be used immediately. If immediate use is not possible, the diluted solution should be
343 stored for up to 36 hours refrigerated at 2° to 8°C (36° to 46°F). Room temperature storage of diluted solution is not
344 recommended.

345 ALDURAZYME does not contain any preservatives; therefore, after dilution with saline in the infusion bags, any
346 unused product or waste material should be discarded and disposed of in accordance with local requirements.

347 ALDURAZYME must not be mixed with other medicinal products in the same infusion.

348 The compatibility of ALDURAZYME in solution with other products has not been evaluated.

349 **17 PATIENT COUNSELING INFORMATION**

350 Patients should be counseled that allergic reactions may occur during ALDURAZYME treatment, including life-
351 threatening anaphylaxis. Premedication and reduction of infusion rate may alleviate those allergic reactions
352 associated with the infusion. The appropriate length of post-infusion monitoring is to be determined by the treating
353 physician based on the individual patient's clinical status and infusion history. [*see Warnings and Precautions (5)*].

354 Patients should be advised to report any adverse reactions experienced while on ALDURAZYME treatment.

355 It is unknown how ALDURAZYME affects women during pregnancy, labor and delivery or while nursing, as no
356 adequate and well controlled clinical studies have been conducted in these patient populations [*see Use in Specific*
357 *Populations (8)*].

358 The full benefits of ALDURAZYME may not be evident for several months to years of treatment. To maintain
359 treatment benefit, ALDURAZYME should be administered on a weekly basis as indicated.

360 Patients should be informed that a registry for MPS I patients has been established in order to better understand the
361 MPS I disease, and to track clinical outcomes of patients with MPS I over time. Patients should be encouraged to
362 participate, and advised that their participation is voluntary and may involve long-term follow-up. Information
363 regarding the registry program may be found at www.MPSIregistry.com or by calling (800) 745-4447.

364 ALDURAZYME is manufactured by:

365 BioMarin Pharmaceutical Inc.
366 105 Digital Drive
367 Novato, CA 94949

368 US License Number 1649

369 ALDURAZYME is distributed by:

370 Genzyme Corporation
371 500 Kendall Street
372 Cambridge, MA 02142

373 1-800-745-4447 (phone)

374 ALDURAZYME® is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.